Healthcare Professionals

Through the IMPRIME Cancer Immunotherapy Clinical Trials, Biothera Pharmaceuticals is evaluating the safety and efficacy of combining Imprime PGG and immune checkpoint inhibitor therapies (anti-PD-1 and anti-PD-L1 antibodies) in multiple cancer indications.

IMPRIME 1 is a Phase 2 clinical study assessing the effectiveness of Imprime PGG in combination with Merck’s Keytruda® (pembrolizumab) in patients with metastatic triple negative breast cancer or advanced melanoma whose disease has progressed following prior treatment with checkpoint inhibitor therapy or chemotherapy. 

Biothera is collaborating with Genentech, Inc., a member of the Roche Group, which is conducting a Phase 2 trial to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s Tecentriq® (atezolizumab) and Avastin® (bevacizumab) to treat patients with metastatic colorectal cancer.

In addition, Biothera Pharmaceuticals is collaborating with the Big Ten Cancer Research Consortium under a grant from Merck, to evaluate Imprime PGG and Keytruda in a Phase 1b/2 non-small cell lung cancer study.

Imprime PGG has been administered to more than 400 cancer patients in multiple combination regimens (checkpoint inhibitors, monoclonal antibodies, chemotherapies).  Imprime PGG has not been shown to exacerbate adverse effects of combination therapies and additive side effects were manageable and reversible.  

Steven O’Day, M.D., The John Wayne Cancer Institute at Providence Saint John’s Health Center
Renowned oncologist and melanoma specialist Dr. Steven O’Day talks about the potential synergies of combining Imprime PGG and checkpoint inhibitor therapy.
Jeremy Graff, Ph.D., Chief Scientific Officer, Biothera Pharmaceuticals
Dr. Graff briefly explains the mechanism of action of Imprime PGG in combination with immune checkpoint inhibitor therapy.
Richard Huhn, M.D., SVP and Medical Director, Biothera Pharmaceuticals
Dr. Huhn outlines the study protocol for Biothera’s clinical trial in melanoma/triple negative breast cancer.
Jeremy Graff, Ph.D., Chief Scientific Officer, Biothera Pharmaceuticals
Dr. Graff presents the scientific evidence for the patient selection biomarker that can help identify those individuals with the best probability of responding to Imprime PGG combination therapy.
Gregory Goldmacher, MD, PhD, MBA, Senior Director, Translational Biomarkers, Merck
Dr. Goldmacher provides an overview irRECIST (Immune-related Response Evaluation Criteria In Solid Tumors) and how to apply this criteria to the evaluation of cancer patients in clinical trials.